Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models - Wikidata - wikimedia - TriplyDB

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

http://www.wikidata.org/entity/Q34253418

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors The treatment landscape in thyroid cancer: a focus on cabozantinib Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Lenvatinib for Anaplastic Thyroid Cancer.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Lenvatinib: A Review in Refractory Thyroid Cancer.Efficacy of lenvatinib in treating thyroid cancer.Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.Lenvatinib in Advanced Hepatocellular Carcinoma.Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Prolonged duration of response in lenvatinib responders with thyroid cancer.Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress Ethanol Extract from Seed Inhibits Angiogenesis Mediated by Platelet Derived Growth Factor Receptor-beta

P2860

Q26751274-4CB3CDD9-0D9A-45FE-9C46-557D2CAFBBE9 Q26764892-E15A01F1-E250-4F81-8379-22C3014CA3A1 Q26796404-2416F6CF-0FD4-4649-A623-092C25E1AAC9 Q26801718-1D2D3B68-0CD6-4FA2-95FB-D29FFE33C435 Q28072655-CAD5E39A-74A2-43AA-898E-20E4E13760BF Q30249385-1FA4DE25-0202-40BD-879B-81C104EBCD32 Q33427289-2AF4DD2C-FE45-4D86-B8F0-BF21C555C808 Q33607412-400DC5AF-28B3-4C43-9649-846664B7155B Q36924717-A212A954-8FFB-4742-87DB-3A1A68765D29 Q36983860-C611BBA8-6988-45FD-852D-4EEC196B07B4 Q37672425-EA0E20DB-0F8F-4768-8AE7-3DADF39D67CD Q37710134-6C3A10C3-5961-4B22-8FE6-F6813021F1A3 Q38543837-8243CFBF-E4A0-4257-BC09-94CB4AF48C33 Q38630967-7191FEF7-3A4A-4972-87C9-9E48BBFBDC5D Q38657760-77BF1B1E-1B12-45D6-9756-28E91D8A19FA Q38729953-BD45D8E5-1D80-48B0-91FC-BD07DB9BA3D2 Q38843403-2401C2FC-25C6-452D-A866-06ADAF4A922D Q41992834-61B7D7B7-20F5-4C8C-B71B-75005D0DF36B Q46573222-3BE93C97-AA58-4F55-96B9-5CBD0D4D4EEC Q47130626-17209F49-B674-4D79-A533-4643B00B34D4 Q47863818-779B7563-E9A9-493C-A665-D905E8AD0CE3 Q48212500-0D48CCCE-787D-45BF-AB72-18B5732EBADA Q49221322-A0AAA935-A3B4-408F-9448-DB24D46BBC76 Q49884642-2FCA0CBD-E407-4C72-8195-2C27D1B8EA58 Q53109364-CB25F227-ABC5-447F-970A-DC10DB82B2E1 Q53520555-3EB35AB7-F317-4223-9C8D-BDF665E9EE28 Q54111915-4C9169CF-51A4-4D18-9AFC-0168556E0464 Q55413273-E6DA97A3-C8BA-4A00-9128-A8F8DEC59031 Q55514052-D2A80B51-7BB0-4870-8AF0-7B8770A6E6EF Q58572423-7F6B3BAB-F172-4972-9C9D-3F8EE6E3740D Q58710790-4CDB1C92-6652-4AB5-ADEB-BA32F8A66F25 Q59137829-2D6D5590-7852-4081-9A39-34A69DBA2256

P2860

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

http://www.wikidata.org/entity/Q34253418

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antitumor activity of lenvatin ...... al human thyroid cancer models

@ast

Antitumor activity of lenvatin ...... al human thyroid cancer models

@en

Antitumor activity of lenvatinib

@nl

type

label

Antitumor activity of lenvatin ...... al human thyroid cancer models

@ast

Antitumor activity of lenvatin ...... al human thyroid cancer models

@en

Antitumor activity of lenvatinib

@nl

prefLabel

Antitumor activity of lenvatin ...... al human thyroid cancer models

@ast

Antitumor activity of lenvatin ...... al human thyroid cancer models

@en

Antitumor activity of lenvatinib

@nl

P1433

Q34253418-A2B77246-2F4A-4597-A26B-1717DB112C8E

P1476

Q34253418-2FE2075B-D2C4-4539-8FBF-B1F90EC2CCE7

P2093

Q34253418-45C2CA82-FCA5-4D05-895E-D11423515161

Q34253418-53F864BF-6803-4AB5-B25D-48BBC16E4B55

Q34253418-9D56306E-6839-4228-9A95-096C50A37477

Q34253418-A881B6E3-B54D-4EAA-B0BB-FDB404821BB3

Q34253418-D0B5E8AC-DCC5-4133-A0E3-24719F43359D

Q34253418-D3243F2C-ABAA-4E72-926C-F4F92698C957

Q34253418-DC8DD761-8A6A-42C0-B0A8-9550B7FEC0FA

P2860

Q34253418-0AABD321-215E-48EA-8F19-735B9FC81FD2

Q34253418-10BCC177-719A-49E2-AD85-7BD77211B8A0

Q34253418-11F36D4B-E026-444D-BE54-6C3A9F6CE35B

Q34253418-130982DB-E0A6-49DC-90DC-89481050D8F8

Q34253418-13F95CFE-B172-48AB-B5A2-0FA9B2E4A810

Q34253418-18732F16-F57A-43CF-BFC1-F9BF8D8FC4CE

Q34253418-1D079CE4-0206-4214-B65E-56FCBDAA2554

Q34253418-23B736AF-2126-4913-A329-9667C37BE005

Q34253418-279384C7-3203-4E52-9E8C-70E1EF8C524D

Q34253418-2C250710-51BA-4A6A-BB13-E22E327CDCFF

P304

Q34253418-A49D2292-2CDB-453C-86E9-DB9F53D285EA

P31

Q34253418-D0C65860-B158-430E-868A-826C7CA28C66

P356

Q34253418-C4E8EC5F-47D9-461A-B3EB-97666A044A72

P478

Q34253418-45ED0026-01CF-4571-AD55-3B36F092FC8E

P50

Q34253418-CDE6FDB8-2366-4A11-A615-B3E3B6D4A51D

Q34253418-FCAA707C-72BF-460D-BCCD-8D4CB93FB7D9

P577

Q34253418-7C66AB6C-6F88-4DD8-A3E6-6A4903E9B94C

P5875

Q34253418-3D077B50-9DC2-4446-901B-10EE5E2B6102

P698

Q34253418-093C80B8-22C9-40CE-808D-84A753006669

P921

Q34253418-F5B57943-154D-4EBD-9870-EC2DD96FE739

P932

Q34253418-2339AC84-81A5-4B6D-99C3-00DA0C58E619

P356

P1433

Journal of Thyroid Research

P1476

Antitumor activity of lenvatin ...... al human thyroid cancer models

@en

P2093

Junji Matsui

http://www.w3.org/2001/XMLSchema#string

Kotaro Kodama

http://www.w3.org/2001/XMLSchema#string

Masao Iwata

http://www.w3.org/2001/XMLSchema#string

Naoko Hata-Sugi

http://www.w3.org/2001/XMLSchema#string

Osamu Tohyama

http://www.w3.org/2001/XMLSchema#string

Takayuki Kimura

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Funahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Angiogenesis in cancer and other diseases

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Angiogenic factors

In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

P304

638747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/638747

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Kiyoshi Okamoto

Yukinori Minoshima

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266681933

http://www.w3.org/2001/XMLSchema#string

P698

25295214

http://www.w3.org/2001/XMLSchema#string

P921

lenvatinib mesylate

P932

4177084

http://www.w3.org/2001/XMLSchema#string